Faculty of Science, Univ. of Ontario Inst. of Technology, Oshawa, ON, Canada.
J Food Sci. 2009 Oct;74(8):M423-30. doi: 10.1111/j.1750-3841.2009.01308.x.
Fermented soy and dairy milk preparations provide a means for delivering lactic acid bacteria and their fermentation products into the diet. Our aims were to test immunomodulatory bioactivity of fermented soy beverage (SB) and dairy milk blend (MB) preparations on human intestinal epithelial cells (IEC) and to determine the impact of freezing medium on culture survival prior to bioactivity analyses. Fermented SB and MB were prepared using pure or mixed cultures of Streptococcus thermophilus ST5, Bifidobacterium longum R0175, and Lactobacillus helveticus R0052. Immunomodulatory bioactivity was assessed by testing selected SB and MB ferments on tumor necrosis factor alpha (TNFalpha)-treated IEC and measuring effects on Interleukin-8 (IL-8) production. Impact of timing of ferment administration relative to this pro-inflammatory challenge was investigated. The most pronounced reductions in IEC IL-8 production were observed when IEC were treated with either SB or MB ferment preparations prior to TNFalpha challenge. These results indicate that freezing-stable MB and SB ferments prepared with selected strains can modulate IEC IL-8 production in vitro, and suggest that yogurt-like fermented soy formulations could provide a functional food alternative to milk-based fermented products.
发酵大豆和乳制品制剂为将乳酸菌及其发酵产物输送到饮食中提供了一种手段。我们的目的是测试发酵大豆饮料 (SB) 和乳制奶混合 (MB) 制剂对人肠上皮细胞 (IEC) 的免疫调节生物活性,并确定在进行生物活性分析之前,冷冻介质对培养物存活率的影响。使用嗜热链球菌 ST5、长双歧杆菌 R0175 和瑞士乳杆菌 R0052 的纯培养物或混合培养物制备发酵 SB 和 MB。通过测试 TNFalpha 处理的 IEC 上选定的 SB 和 MB 发酵物,并测量对白细胞介素 8 (IL-8) 产生的影响来评估免疫调节生物活性。研究了发酵剂给药相对于这种促炎挑战的时间的影响。当 IEC 在 TNFalpha 挑战之前用 SB 或 MB 发酵制剂处理时,观察到 IEC IL-8 产生的最大降低。这些结果表明,用选定的菌株制备的冷冻稳定的 MB 和 SB 发酵物可以在体外调节 IEC IL-8 的产生,并表明类似于酸奶的发酵大豆配方可以为基于牛奶的发酵产品提供功能性食品替代。